Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Longxiang Pingchuan is a Traditional Chinese Medicine (TCM) formulation developed by Dongzhimen Hospital of the Beijing University of Traditional Chinese Medicine. It is primarily administered in capsule form and is indicated for the treatment of bronchial asthma, specifically targeting the 'phlegm and blood stasis blocking the lung' syndrome during the chronic phase of the disease. The therapeutic approach of the formulation involves resolving phlegm, promoting blood circulation to remove stasis, and calming wheezing (Pingchuan). Clinical evaluation, such as the trial ChiCTR2200066722, has focused on assessing its efficacy and safety in improving lung function and reducing respiratory symptoms in patients with chronic bronchial asthma compared to standard treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Longxiang Pingchuan.